Current Report Filing (8-k)
January 08 2013 - 2:15PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January
8, 2013
SYNTHETIC BIOLOGICS, INC.
(Exact name of registrant as specified in
its charter)
Nevada
|
|
1-12584
|
|
13-3808303
|
(State or other jurisdiction of incorporation)
|
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
3985 Research Park Drive, Suite 200, Ann
Arbor, Michigan 48108
(Address of principal executive offices) (Zip
Code)
Registrant’s telephone number, including
area code: (734) 332-7800
(Former name or former address, if changed
since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01. Regulation
FD Disclosure
Jeffrey Riley, Chief Executive Officer and President of Synthetic
Biologics, Inc. (the “Company”), will be making a presentation on January 9, 2013 at the Sixth Annual OneMedForum San
Francisco 2013, as well as making several investor presentations during the next few weeks. In connection with the presentations,
Mr. Riley intends to discuss the slide presentation furnished as Exhibit 99.1 hereto, which is incorporated herein by reference.
The slide presentation attached as Exhibit
99.1 to this Report includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995,
as amended, indicating that certain statements contained in the slide presentation or in the press release are “forward-looking”
rather than historical.
The information included in this Item 7.01
and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference
in such a filing. The Company undertakes no duty or obligation to update or revise information included in this Report or any of
the Exhibits.
Item 9.01. Financial
Statements and Exhibits
(d) Exhibits
The following exhibit
is being filed as part of this Report.
Exhibit
Number
|
Description
|
|
|
99.1
|
Presentation materials to be provided at Synthetic Biologics, Inc.’s investor presentations
|
|
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
SYNTHETIC BIOLOGICS, INC.
|
|
|
Date: January 8, 2013
|
By:
/s/ C. Evan Ballantyne
|
|
Name: C. Evan Ballantyne
|
|
Title: Chief Financial Officer
|
EXHIBIT INDEX
Exhibit
Number
|
Description
|
|
|
99.1
|
Presentation materials to be provided at Synthetic Biologics, Inc.’s investor presentations
|
|
|
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Synthetic Biologics (AMEX:SYN)
Historical Stock Chart
From Jul 2023 to Jul 2024